हिंदी में पढ़ें
Income Tax Calculator
Personal Loan Calculator
Car Loan Calculator
Home Loan Calculator
MF Returns Calculator
Dr Reddy's Laboratories News
Dr Reddy's Laboratories
Sputnik V clinical trial is about to begin: Saumen Chakraborty, CFO, Dr Reddy’s Laboratories
Fri, Oct 30, 2020
Dr Reddy’s has launched 20 products so far in this financial year, says Saumen Chakraborty, Chief Financial Officer, Dr Reddy's Laboratories. During a chat with Swati Khandelwal, Zee Business, Chakraborty said, the trial of sputnik about to start and we have around 100 patients in Phase-II and 1,500 in phase-III.
Trials of Russian Sputnik-V vaccine may end as early as March: Dr Reddy''s
Wed, Oct 28, 2020
Drugmaker Dr Reddy`s Laboratories Ltd on Wednesday rolled out a preliminary timeline for the India trials of Russia`s coronavirus vaccine candidate, with the late-stage expected to be completed by as early as March 2021.
Dr Reddy's seeks DCGI nod for conducting phase-3 clinical trial of Russian COVID-19 vaccine Sputnik V
Sat, Oct 03, 2020
The Hyderabad-based Dr Reddy's Laboratories has applied to the Drugs Controller General of India for permission to conduct phase-3 human clinical trials of the Russian vaccine Sputnik V against COVID-19 in India, sources said.
Dr Reddy's Share price skyrockets near 13 pct; stock market experts suggest this strategy to mint money
Fri, Sep 18, 2020
Dr Reddy's share price has skyrocketed around 13 per cent in the intraday trade session. Dr Reddy's share price today shot up over Rs 625 to hit Rs 5,423 per share mark today.
Stocks in Focus on September 18: Dr Reddy's, Cipla, Lupin, Happiest Minds Technologies to HDFC Bank; here are expected newsmakers of the day
Fri, Sep 18, 2020
Stocks in Focus on September 18: Dr Reddy's, Cipla, Lupin, Happiest Minds Technologies, HDFC Bank, etc. are expected newsmakers throughout the intraday trade session.
Dr Reddy's Laboratories Q1 net profit soars 45% to Rs 663 crore
Mon, Jul 29, 2019
Pharma major Dr Reddy's Laboratories (DRL) on Monday reported a handsome 45.31 per cent growth in net profit for the first quarter ended June.
Dr Reddys to spend upto $300 million on R&D in FY 20
Mon, May 20, 2019
The R&D spend for the quarter (January-March FY 19) is Rs 366 crore, that is USD 53 million and EBIT 9.19 per cent of the sales for the quarter, said Saumen Chakraborty, President, CFO and global head (HR) of Dr Reddy.
Dr Reddy's, KKR appoint ex Axis Bank chief Shikha Sharma as independent director
Fri, Feb 01, 2019
Sharma will advising them on areas for business growth, value-creation opportunities and strategic mergers and acquisitions, an official statement said.
Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018
Mon, Dec 31, 2018
The sector has been volatile throughout the year due to constant news flow in the markets. Some giants of the sector witnessed objections over their manufacturing plants and medicine pricing in the U.S. markets.
Big blow to Dr Reddy's over opioid addiction treatment block in US; share price tanks a whopping 11%
Mon, Jul 16, 2018
Analysts at Jefferies believe injunction is a negative surprise for Dr Reddy’s and risks for FY20-22 EPS estimates have increased after the ruling. retain “underperform”, cuts TP to 1,850 rupees from 1,910 rupees
FAST MONEY: Phoenix Mills, Biocon among 20 intraday money-making ideas
Mon, Jun 25, 2018
S&P500 mini futures fell as much as 0.5 per cent in early trade while MSCI's broadest index of Asia-Pacific shares outside Japan fell 0.2 per cent. Japan's Nikkeilost 0.4 percent.
Dr Reddy's last day on Sensex; stock rallies 20% in 8 sessions
Fri, Jun 15, 2018
Dr Reddy's share price gained as much as 20 per cent in the last 8 sessions, thanks to a renewed optimism on the sector. Nifty Pharma index itself gained 14 per cent during the same period. In Friday's trade, Nifty Pharma was the top sectoral gainer, led by gains in Dr Reddy's.
Sensex, Nifty reverse gains; Rupee at 10-week low as US Fed signals rate hike
Thu, Sep 21, 2017
In pre-market opening, the 31-scrip index was trading lower at 32,406-level and that of 51-scrip index was below 10,140-mark.
Dr Reddy's Q4 net profit rises by 319%
Fri, May 12, 2017
GV Prasad, Co-Chairman and CEO of Dr Reddy's Laboratories said, “FY17 has been challenging year due to lack of new product approvals for the US market. However, our other geoghraphies delivered good performance with several new product launches.”
Dr Reddy's Laboratories Q4 review: Here's what to expect
Fri, May 12, 2017
In Q3FY17, the company reported consolidated net profit of Rs 492.3 crore, down 15.94% year-on-year compared to Rs 585.7 crore in the corresponding period of the previous year.
Next set of Q4 corporate earnings, macro data, French elections result to drive equities this week
Sun, May 07, 2017
According to experts, the stock markets this week will be guided by the fourth quarter (Q4) corporate earnings, macroeconomic data and French elections results.
Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore
Sat, Feb 04, 2017
GV Prasad, Co-chairman of Dr Reddy's Laboratories said, "Our performance in Q3 has delivered a modest sequential revenue growth of 3% over the previous quarter. Our EBITDA has improved significantly from the last quarter to Rs 8.8 billion, on the back of enhanced emphasis on operational efficiencies and controlling of SG&A cost across all our business."
USFDA to re-audit Dr Reddy's three plants in first quarter of 2017
Thu, Jan 12, 2017
US Food and Drug Administration (USFDA) will re-audit three manufacturing facilities of Dr Reddy's Laboratories in the current quarter.
What would a Hillary Clinton win mean for Indian Pharma?
Mon, Nov 07, 2016
The global generics sector saw a significant de-rating in YTD (year-to-date) in the CY2016 with 1-year forward P/E (price over equity) contracting by 34%, with the past one month itself witnessing an 11%.
Pharma stocks fall sharply as US drug pricing investigation nears completion
Fri, Nov 04, 2016
Media reports suggest that the US Congress investigation into price hikes, that began in October 2014, may be nearing completion, culminating into charges of price collusion against companies / individuals by the year end.